Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Blood (2025) 146 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2025-1646

Published: 2025

Journal Articles

Simultaneous high-throughput identification of myeloid leukemia driver mutation-derived public neoantigens and cognate functional TCRs for TCR-T therapy

Ho Ngai, Duncheng Wang, Yibin Chen, Xizeng Mao, Zhen Zuo, Shoudan Liang, Yanqing Huang, Celine Kerros, Luca Zammataro, Priya Koppikar, Noah Tubo, Jeffrey Molldrem

Blood (2025) 146 (Supplement 1): 259.

https://doi.org/10.1182/blood-2025-259

Published: 2025

Journal Articles

Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in Myelodysplastic Syndromes after stem cell transplant

Yu-Hsiang Chen, Timothy Bi, Minhang Xu, Jaehyun Lee, Wesley Lu, Mengchuan Zhuang, Alejandro Marinos Velarde, Hui Yang, Gheath Alatrash, Gabriela Rondon, Elizabeth Shpall, Fatima Jelloul, Frances Cervoni-Curet, Celine Kerros, Priya Koppikar, Jeffrey Molldrem, Guillermo Garcia-Manero, Ankit Patel, Pavan Bachireddy

Blood (2025) 146 (Supplement 1): 674.

https://doi.org/10.1182/blood-2025-674

Published: 2025

Journal Articles

TCR-T cells targeting a public neoantigen produced by the SF3B1 K700E mutation kill SF3B1-mutant AML/MDS

Noah Tubo, Duncheng Wang, Qiuming He, Yibin Chen, Ho Ngai, Yanqing Huang, Celine Kerros, Xizeng Mao, Shoudan Liang, Hong He, Gheath Alatrash, Omar Abdel-Wahab, Priya Koppikar, Jeffrey Molldrem

Blood (2025) 146 (Supplement 1): 2363.

https://doi.org/10.1182/blood-2025-2363

Published: 2025

Journal Articles

TCR-T cells expressing a TCR recognizing the MPO propeptide-derived MPO132-140:HLA-a*02:01 specifically kill AML and spare healthy myeloid cells

Yibin Chen, Yanqing Huang, Xizeng Mao, Shoudan Liang, Priya Koppikar, Noah Tubo, Jeffrey Molldrem

Blood (2025) 146 (Supplement 1): 2362.

https://doi.org/10.1182/blood-2025-2362

Published: 2025

Journal Articles

Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 343.

https://doi.org/10.1182/blood-2024-198639

Published: 2024

Journal Articles

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Blood (2023) 142 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2023-189966

Published: 2023

Journal Articles

High-Throughput Identification of Graft-Vs-Leukemia TCRs in AML Patient Samples after Allogeneic Stem Cell Transplantation

Noah J Tubo, Duncheng Wang, Qiuming He, Yibin Chen, Ho Ngai, Yanqing Huang, Celine Kerros, Xizeng Mao, Shoudan Liang, Sachet Shukla, Arnau Peris Cuesta, Pavan Bachireddy, Julio Alcantara Montiel, Gheath Alatrash, Priya Koppikar, Jeffrey J. Molldrem

Blood (2023) 142 (Supplement 1): 7168.

https://doi.org/10.1182/blood-2023-190330

Published: 2023

Journal Articles

A Public Neoantigen Produced By the SF3B1 K700E Mutation Is a Bona Fide T Cell Target in AML/MDS

Noah J Tubo, Duncheng Wang, Qiuming He, Yibin Chen, Ho Ngai, Yanqing Huang, Celine Kerros, Xizeng Mao, Shoudan Liang, Hong He, Gheath Alatrash, Priya Koppikar, Jeffrey J. Molldrem

Blood (2023) 142 (Supplement 1): 6816.

https://doi.org/10.1182/blood-2023-190199

Published: 2023

Journal Articles

Characterization of Changes in the T-Cell Receptor Repertoire in Patients with Acute Myeloid Leukemia with Durable Remission Following Allogeneic Stem Cell Transplant

Ronald M. Paranal, MD, Hagop M. Kantarjian, MD, Alexandre Reuben, PhD, Celine Kerros, PhD, Priya Koppikar, PhD, Latasha Little, BS, Curtis Gumbs, Nicholas J. Short, MD, Jorge E. Cortes, MD, Elias Jabbour, MD, Jeffrey J. Molldrem, P. Andrew Futreal, PhD, Ghayas C. Issa, MD

Blood (2019) 134 (Supplement_1): 5186.

https://doi.org/10.1182/blood-2019-129911

Published: 2019

Journal Articles

Evaluation of a FLT3 Bite® for Acute Myeloid Leukemia

Rebecca Goldstein, PhD, Anja Henn, Priya Koppikar, PhD, Ivonne Archibeque, BA, Brendon Frank, Mercedesz Balazs, Christoph Dahlhoff, PhD, Tobias Raum, PhD, Chi-Ming Li, PhD, Joachim Wahl, PhD, Dan Rock, Oliver Thomas, BSc, Christine Karbowski, PhD, Christina Krupka, PhD, Marion Subklewe, MD, Angela Coxon, PhD, Tara Chapman-Arvedson

Blood (2017) 130 (Supplement 1): 1354.

https://doi.org/10.1182/blood.V130.Suppl_1.1354.1354

Published: 2017

Journal Articles

JAK1 As a Convergent Regulator of Hematopoietic Stem Cell Function and Stress Hematopoiesis

Maria Kleppe, PhD, Matthew H Spitzer, PhD, Sheng Li, PhD, Lauren Dong, M.S., Efthymia Papalexi, Corinne Hill, M.S, Sofie De Groote, M.S., Matthew Keller, M.S., Priya Koppikar, PhD, Franck Rapaport, PhD, Jorge Gandara, Christopher E. Mason, PhD, Garry P. Nolan, Prof, PhD, Ross L. Levine, MD

Blood (2016) 128 (22): 722.

https://doi.org/10.1182/blood.V128.22.722.722

Published: 2016

Journal Articles

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Blood (2015) 126 (22): 2479–2483.

https://doi.org/10.1182/blood-2015-03-635821

Published: 2015

Includes: Supplemental data

Journal Articles

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Sara C Meyer, MD PhD, Matthew D Keller, BS, Priya Koppikar, PhD, Olga A Guryanova, MD PhD, Maria Kleppe, PhD, Anna Sophia McKenney, MPH, William R Sellers, MD, Francesco Hofmann, PhD, Fabienne Baffert, Christoph Gaul, PhD, Thomas Radimerski, PhD, Ross L Levine, MD

Blood (2014) 124 (21): 160.

https://doi.org/10.1182/blood.V124.21.160.160

Published: 2014

Journal Articles

Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN Patients

Kaitlyn R Shank, B.S., Priya Koppikar, PhD, Neha Bhagwat, PhD, Matthew D Keller, B.S., Franziska Michor, PhD, Ross L Levine, MD, Laura De Vargas Roditi, PhD

Blood (2014) 124 (21): 911.

https://doi.org/10.1182/blood.V124.21.911.911

Published: 2014

Journal Articles

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Neha Bhagwat, Priya Koppikar, Matthew Keller, Sachie Marubayashi, Kaitlyn Shank, Raajit Rampal, Jun Qi, Maria Kleppe, Hardik J. Patel, Smit K. Shah, Tony Taldone, James E. Bradner, Gabriela Chiosis, Ross L. Levine

Blood (2014) 123 (13): 2075–2083.

https://doi.org/10.1182/blood-2014-01-547760

Published: 2014

Includes: Supplemental data

Journal Articles

Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms

Qiang Jeremy Wen, PhD, MD, Benjamin Goldenson, Sebastien Malinge, PhD, Brady L Stein, MD MHS, Terra L Lasho, MT, (ASCP), Lawrence Breyfogle, Rachael Schultz, Qiong Yang, Laure gilles-Gendre, Priya Koppikar, Omar Abdel-Wahab, MD, Benjamin L. Ebert, MD, PhD, Animesh Pardanani, MBBS, PhD, Sandeep Gurbuxani, MBBS, PhD, Ross L. Levine, MD, Ann Mullally, MD, Ayalew Tefferi, MD, John D Crispino, PhD

Blood (2013) 122 (21): 109.

https://doi.org/10.1182/blood.V122.21.109.109

Published: 2013

Journal Articles

Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo

Ross L. Levine, Priya Koppikar, Sachie Marubayashi, Neha Bhagwat, Tony Taldone, PhD, Christopher Y. Park, MD, PhD, Gabriela Chiosis, PhD

Blood (2012) 120 (21): 805.

https://doi.org/10.1182/blood.V120.21.805.805

Published: 2012

Journal Articles

Induction of Megakaryocyte Polyploidization in Combination with JAK Inhibition As a Novel Therapeutic Strategy for Myeloproliferative Neoplasms

Qiang Jeremy Wen, MD, PhD, Benjamin Goldenson, Sebastien Malinge, PhD, Priya Koppikar, Ross L Levine, MD, Ayalew Tefferi, MD, John Crispino, PhD

Blood (2011) 118 (21): 64.

https://doi.org/10.1182/blood.V118.21.64.64

Published: 2011

Journal Articles

Inhibition of AKT Signaling Potently Inhibits the Growth of JAK and MPL-Mutant Cells in the Myeloproliferative Neoplasms In Vitro and In Vivo,

Irum Khan, MBBS, Zan Huang, PhD, Qiang Jeremy Wen, MD, PhD, Priya Koppikar, Ross L Levine, MD, Ayalew Tefferi, MD, John Crispino, PhD

Blood (2011) 118 (21): 3862.

https://doi.org/10.1182/blood.V118.21.3862.3862

Published: 2011

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Simultaneous high-throughput identification of myeloid leukemia driver mutation-derived public neoantigens and cognate functional TCRs for TCR-T therapy

Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in Myelodysplastic Syndromes after stem cell transplant

TCR-T cells targeting a public neoantigen produced by the SF3B1 K700E mutation kill SF3B1-mutant AML/MDS

TCR-T cells expressing a TCR recognizing the MPO propeptide-derived MPO132-140:HLA-a*02:01 specifically kill AML and spare healthy myeloid cells

Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

High-Throughput Identification of Graft-Vs-Leukemia TCRs in AML Patient Samples after Allogeneic Stem Cell Transplantation

A Public Neoantigen Produced By the SF3B1 K700E Mutation Is a Bona Fide T Cell Target in AML/MDS

Characterization of Changes in the T-Cell Receptor Repertoire in Patients with Acute Myeloid Leukemia with Durable Remission Following Allogeneic Stem Cell Transplant

Evaluation of a FLT3 Bite® for Acute Myeloid Leukemia

JAK1 As a Convergent Regulator of Hematopoietic Stem Cell Function and Stress Hematopoiesis

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN Patients

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms

Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo

Induction of Megakaryocyte Polyploidization in Combination with JAK Inhibition As a Novel Therapeutic Strategy for Myeloproliferative Neoplasms

Inhibition of AKT Signaling Potently Inhibits the Growth of JAK and MPL-Mutant Cells in the Myeloproliferative Neoplasms In Vitro and In Vivo,

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only